Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Anterior Segment > Severe trench pattern scarring post-MIGS predicts need for glaucoma medications
  • Anterior Segment

Severe trench pattern scarring post-MIGS predicts need for glaucoma medications

Kelsey Moroz

Severe scarring in a trench pattern, as observed using anterior segment optical coherence tomography (AS-OCT), predicts the need for glaucoma medications after minimally invasive glaucoma surgery (MIGS), according to a study.

Regular monitoring of scarring responses with AS-OCT and clinical examinations is crucial for identifying patients who may require additional medication post-surgery.

The study examined 73 eyes from 67 patients, with at least 6 months of follow-up after microincisional trabeculectomy (MIT; n = 41) or gonioscopy-assisted transluminal trabeculotomy (GATT; n=32). Structural changes in the TM were evaluated using AS-OCT at 1, 3, and 6 months post-surgery, focusing on scarring severity and patterns. The study also analyzed the relationship between scarring, need for medications, and surgical outcomes using multivariate regression.

MIT and GATT significantly reduced intraocular pressure (IOP) and medication use, with a final IOP of 15±3.2 mm Hg at an average follow-up of 8±3.2 months. Mild scarring was more common in MIT, while severe scarring was more frequent in GATT (over 65% vs 31%, P < 0.001). The trench pattern of scarring was more common in GATT eyes (>50%). Severe scarring in a trench pattern predicted the need for additional IOP-controlling medications.

Reference
Rao A, Mukherjee S. Healing responses at the angle after micro-invasive glaucoma surgery-an AS-OCT study. PLoS One. 2024;19(6):e0305740. doi: 10.1371/journal.pone.0305740. PMID: 38935644; PMCID: PMC11210766.

Share

Related Content

  • Anterior Segment

AS-OCT analysis shows deeper corneal layer thickening in pseudoexfoliation syndrome

  • Anterior Segment

Study compares tear meniscus measurements in patients with low vitamin D levels

  • Anterior Segment

Global AS-OCT research surges, highlighting growth in AI and imaging innovation

  • Anterior Segment

Age and sex influence key anterior segment metrics in healthy eyes

  • Anterior Segment

Ophthalmologic interventions can improve quality of life in hospice care

  • Anterior Segment

AI’s potential for early diagnosis of vitreoretinal lymphoma

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon